On Friday, Biogen Inc (BIIB) stock saw a modest uptick, ending the day at $160.51 which represents a slight increase of $0.68 or 0.43% from the prior close of $159.83. The stock opened at $160.72 and ...

Bearish flow noted in Biogen (BIIB) with 1,136 puts trading, or 1.1x expected. Most active are Apr-25 160 puts and 11/29 weekly 162.5 calls, ...

Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

On Wednesday, Biogen Inc (BIIB) stock saw a modest uptick, ending the day at $159.83 which represents a slight increase of $2.14 or 1.36% from the prior close of $157.69. The stock opened at $158.65 ...

Despite developing the drug Leqembi that slows the brain-destroying disease — a historic feat — Eisai and its partner Biogen Inc. have faced a rocky rollout due to logistical issues, insurance ...

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

Biogen will face ongoing challenges as these expectations are ... Price Action: BIIB stock is down 1.15% at $158.15 at the ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Needham & Company LLC from a “buy” ...

The firm has a market cap of $23.31 billion, a P/E ratio of 14.45, a P/E/G ratio of 1.51 and a beta of -0.06. The firm’s 50 ...

Highlights:,Biogen Inc. (BIIB) has underperformed the broader market and key healthcare ETFs in recent years.,The company’s ...